Raymed Labs Ltd.
Snapshot View

1.65 ▼0%

16 May 2022, 04:00:00 PM

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.raymedlab.com
Market Cap 0.71 Cr.
Enterprise Value(EV) 2.88 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) -0.19 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share -4.89 Trailing Twelve Months Ending 2021-12
Price to Book Value -0.34 Calculated using Price: 1.65
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 0.43 Cr. 4,273,500 Shares
FaceValue 10
Company Profile

Raymed Labs was established in 1994 as a pharmaceutical company with emphasis on injectables with state of the art manufacturing facilities. the company is located at Dehradun Road, Saharanpur, UP. Manufacturing pharmaceutical products, as such, is a specialized job, however, manufacturing of injectables is even more difficult since they are normally given during a life saving situation thus their quality standards are much more stringent. Raymed’s quality quickly won the trusts of doctors and it established itself as one of the leading quality manufacturers of medicines in the area.

Raymed strives on a well organized management team of skilled and highly trained professionals from different streams.  This team contains chemists, pharmacists, marketing professionals with in-depth knowledge & requirements for human and animal products.

Products range:

  • RAMPICILLIN - Ampicillin, a semisynthetic penicillin
  • RAMPICLOX - Equal quantities of Ampicillin and Cloxacillin
  • RAMPIMOX - Equal quantities of Amoxycillin and Cloxacillin
  • RAMYKACIN - Amikacin Sulphate
  • OXYTETRACYCLINE - The most common Antibiotic in Veterinary Practice
  • RAMYFENAC-Diclofenac Sodium. It is a potent non steroidal Anti-inflammatory, Analgesic & Antipyretic for human use
  • RAMAMINE- Chlorpheniramine Maleate.  The most potent & effective Anti-histaminic for veterinary use
  • RAMYDEX-Dexamethasone Sodium Phosphate. Anti-inflammatory, Anti-allergic, Gluco-corticoid adjuvant with Antibiotic therapy
  • RAMYCIN-Gentamycin Sulphate
  • RAMYPINE - Atropin Sulphate.  The drug has anticholenergic effect in veterinary use.
  • RAMYCHLOR - Chloramphenicol
  • REALOPAR - Paracetamol
  • RAYVIL - Pheniramine Maleate
  • RAMALGIN-P - Phenylbutazone and Analgin with Lignocaine: A unique combination of highly effective analgesic, antispasmodic, anti-inflammatory & Antipyretic for veterinary use.
  • RAMYSCAB - Sulphur with Benzyl Benzoate in Lidocaine base: An ideal treatment of Scabies & other dermal problems in animals
  • RAMYVIT PLEX - Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B12 with Liver Extract:  crude injection and ideal treatment of Scabies & other dermal problems in animals

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
1 Month
+4.43%
3 Month
+14.58%
6 Month
+73.68%
1 Year
+77.42%
2 Year
+70.10%
5 Year
-36.05%
10 Year
-93.58%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%)
Return on Capital Employed (%) -12.72 -13.45 -7.11 -15.55 -26.39 -41.34 -58.42 -105.49 -94.34
Return on Assets (%) -11.47 -12.03 -6.08 -12.90 -17.98 -20.71 -20.01 -21.34 -27.07

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds -2 -2 -2 -2 -2 -2 -2 -2 -2 -2
Non Curr. Liab.
Curr. Liab. 2 2 2 2 2 2 2 2 2 2
Minority Int.
Equity & Liab. 1 0 0 0 0 0 0 0 0 0
Non Curr. Assets 0 0 0 0 0 0 0 0 0 0
Curr. Assets 0 0 0 0 0 0 0 0 0 0
Misc. Exp. not W/O
Total Assets 1 0 0 0 0 0 0 0 0 0

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales
Other Income 0 0 0 0 0 0 0 0
Total Income 0 0 0 0 0 0 0 0
Total Expenditure 0 0 0 0 0 0 0 0 0 0
PBIDT 0 0 0 0 0 0 0 0 0 0
Interest
Depreciation 0 0 0 0 0 0 0
Taxation
Exceptional Items 0 0 0 0 0 0
PAT 0 0 0 0 0 0 0 0 0 0
Adjusted EPS 0 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0
Cash Fr. Inv. 0
Cash Fr. Finan. 0 0 0 0
Net Change 0 0 0
Cash & Cash Eqvt 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 28.36 28.36 28.36 28.36 28.36 28.36 28.36 28.36 28.36
Public 71.64 71.64 71.64 71.64 71.64 71.64 71.64 71.64 71.64
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 14 May 2022
Board Meeting Intimation for Approval For Audited Financial Results For The Quarter And Year Ended As On 31.03.2022
RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve Audited Financial Results for the quarter and year ended as on 31.03.2022
Sat, 23 Apr 2022
Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayRAYMED LABS LTD.
2CINL24111UP1992PLC014240
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 21633.07
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Priyanka Sisodia
Designation: Company Secretary
EmailId: raymedlabs@rediffmail.com
Name of the Chief Financial Officer: Ajai Goyal
Designation: Chief Financial Officer
EmailId: raymedlabs@rediffmail.com

Date: 23/04/2022

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Fri, 22 Apr 2022
Certificate Under Reg 40(9) For The Year Ended 31.03.2022
Certificate under Reg 40(9) for the year ended 31.03.2022

Technical Scans View Details

Mon, 16 May 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Opening at High Opening at High
Opening at Low Opening at Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%